DA
AVIR icon

Denali Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Denali Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,000
Closed -$54K – 456
2023
Q3 		$54K Hold
18,000
– – 0.02% 290
2023
Q2 		$67.3K Hold
18,000
– – 0.02% 280
2023
Q1 		$60.3K Hold
18,000
– – 0.03% 206
2022
Q4 		$86.6K Buy
18,000
+13,600
+309% +$68.8K 0.04% 174
2022
Q3 		$25K Buy
+4,400
New +$33.7K 0.01% 269

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Denali Advisors's AVIR Position: Q4 2023 in Review

Denali Advisors sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 18,000 shares — an estimated $54K sold.

Denali Advisors first reported a position in AVIR in Q3 2022 and held it in 5 quarters. The position peaked at $86.6K in Q4 2022. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Denali Advisors reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Denali Advisors sold 18,000 Atea Pharmaceuticals shares in Q4 2023, an estimated $54K.
  • Denali Advisors first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Denali Advisors's Atea Pharmaceuticals position peaked at $86.6K in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Denali Advisors's 13F filing for Q4 2023, filed 19 Jan 2024.